Literature DB >> 19092292

Effects of estrogen and estrogen-progesteron on serum nitric oxide metabolite concentrations in post-menopausal women.

G Bednarek-Tupikowska1, U Tworowska-Bardzinska, K Tupikowski.   

Abstract

UNLABELLED: Estrogens have some anti-atherosclerotic properties and they influence nitric oxide (NO) production. The aim of this study was to determine NOx levels in post-menopausal women and the effect of estrogen/estrogen-progesteron therapy (ET/EPT) on plasma NO levels. Eighty postmenopausal women (M1) comprising 26 with surgically induced menopause (ET1), mean age 50.9+/-2.9 yr, and 54 with physiological menopause (EPT1), mean age 50.5+/-3.0 yr, were studied. Forty healthy pre-menopausal women, mean age 48.3+/-2.3 yr were the controls (C). The post-menopausal women were treated for 4 months: group ET1 with ET and group EPT1 with EPT. Serum estradiol (E2), FSH, NOx and lipid profile before and after therapy were measured. NOx levels were lower in group M1 than in group C (8.75+/-1.57 vs 10.27+/-2.62, p<0.01) and increased after hormonal therapy (10.65+/-2.38). NOx concentration showed significant positive correlation with E2 (r=0.25, p<0.05). Total cholesterol (240.9+/-43.2), LDL-cholesterol (155.2+/-33.6), triglycerides (124.8+/-54.1), and apolipoprotein B (1.52+/-0.33) were higher in group M1 than in group C (223.1+/-44.3, 133.0+/-38.2, 108.3+/-52.9, and 1.12+/-0.36, respectively), and after ET/EPT they decreased to the values observed in group C. There were no correlations between NO and lipids or apolipoproteins.
CONCLUSIONS: ET and EPT improve NOx synthesis and endothelial relaxation. Medroxyprogesterone acetate added to E2 does not significantly influence NOx levels.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19092292     DOI: 10.1007/BF03346435

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  40 in total

Review 1.  Vascular effects of hormones.

Authors:  P Collins
Journal:  Maturitas       Date:  2001-02-28       Impact factor: 4.342

2.  The long-term effects of oral and transdermal postmenopausal hormone replacement therapy on nitric oxide, endothelin-1, prostacyclin, and thromboxane.

Authors:  O Ylikorkala; B Cacciatore; I Paakkari; M J Tikkanen; L Viinikka; J Toivonen
Journal:  Fertil Steril       Date:  1998-05       Impact factor: 7.329

3.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

Review 4.  Prostacyclin and nitric oxide.

Authors:  R J Gryglewski
Journal:  Acta Haematol Pol       Date:  1994

5.  Effects of estrogen in the regulation of nitric oxide pathway during development of hypertension in rats.

Authors:  Marie-Françoise Doursout; Jacques E Chelly
Journal:  Proc West Pharmacol Soc       Date:  2002

6.  Long-term effect of estrogen replacement on plasma nitric oxide levels: results from the estrogen in the prevention of atherosclerosis trial (EPAT).

Authors:  Juliana Hwang; Wendy J Mack; Min Xiang; Alex Sevanian; Roger A Lobo; Howard N Hodis
Journal:  Atherosclerosis       Date:  2005-02-19       Impact factor: 5.162

7.  Effects of oestradiol and oestroprogestin on erythrocyte antioxidative enzyme system activity in postmenopausal women.

Authors:  Grazyna Bednarek-Tupikowska; Urszula Tworowska; Iwona Jedrychowska; Barbara Radomska; Krzysztof Tupikowski; Bozena Bidzinska-Speichert; Andrzej Milewicz
Journal:  Clin Endocrinol (Oxf)       Date:  2006-04       Impact factor: 3.478

8.  Effects of long-term estrogen replacement therapy versus combined hormone replacement therapy on nitric oxide-dependent vasomotor function.

Authors:  Hannu Jokela; Prasun Dastidar; Riikka Rontu; Anne Salomäki; Klaus Teisala; Terho Lehtimäki; Reijo Punnonen
Journal:  J Clin Endocrinol Metab       Date:  2003-09       Impact factor: 5.958

9.  Circulating nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17 beta-estradiol and norethisterone acetate. A two-year follow-up study.

Authors:  M Rosselli; B Imthurn; P J Keller; E K Jackson; R K Dubey
Journal:  Hypertension       Date:  1995-04       Impact factor: 10.190

10.  Up-regulation of nitric oxide synthase by estradiol in human aortic endothelial cells.

Authors:  K Hishikawa; T Nakaki; T Marumo; H Suzuki; R Kato; T Saruta
Journal:  FEBS Lett       Date:  1995-03-06       Impact factor: 4.124

View more
  5 in total

1.  Short-term oral progesterone administration antagonizes the effect of transdermal estradiol on endothelium-dependent vasodilation in young healthy women.

Authors:  Jennifer A Miner; Emily R Martini; Michael M Smith; Vienna E Brunt; Paul F Kaplan; John R Halliwill; Christopher T Minson
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-08-19       Impact factor: 4.733

Review 2.  Women-specific factors to consider in risk, diagnosis and treatment of cardiovascular disease.

Authors:  Ronée E Harvey; Kirsten E Coffman; Virginia M Miller
Journal:  Womens Health (Lond)       Date:  2015-03

3.  Forearm vasodilatation to a β2 -adrenergic receptor agonist in premenopausal and postmenopausal women.

Authors:  Ronée E Harvey; Sushant M Ranadive; Jacqueline K Limberg; Sarah E Baker; Wayne T Nicholson; Timothy B Curry; Jill N Barnes; Michael J Joyner
Journal:  Exp Physiol       Date:  2020-04-16       Impact factor: 2.969

4.  Increasing dietary nitrate has no effect on cancellous bone loss or fecal microbiome in ovariectomized rats.

Authors:  Melissa N Conley; Cooper Roberts; Thomas J Sharpton; Urszula T Iwaniec; Norman G Hord
Journal:  Mol Nutr Food Res       Date:  2017-03-30       Impact factor: 5.914

5.  Sex-Based Evaluation of Lipid Profile in Postoperative Adjuvant Mitotane Treatment for Adrenocortical Carcinoma.

Authors:  Sarah Allegra; Soraya Puglisi; Chiara Borin; Francesco Chiara; Vittoria Basile; Anna Calabrese; Giuseppe Reimondo; Silvia De Francia
Journal:  Biomedicines       Date:  2022-08-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.